Recruiting

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(5 sites)

United States

Maryland Proton Treatment Center, Baltimore, Maryland

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland

Upper Chesapeake Health, Bel Air, Maryland

Central Maryland Radiation Oncology, Columbia, Maryland

Baltimore Washington Medical Center, Glen Burnie, Maryland